![](/wp-content/uploads/2018/10/yVmpjQIERsWvXQnliSCG.png)
$599
New Lilly Ph1 Trial; Likely GGG Tri-agonist
Lilly has initiated a new Ph1 trial evaluating an unknown compound (LY3437943) vs. Trulicity in T2DM patients. Below, FENIX has conducted an analysis to help identify the compound and potential MOA.
Lilly has initiated a new Ph1 trial evaluating an unknown compound (LY3437943) vs. Trulicity in T2DM patients. Below, FENIX has conducted an analysis to help identify the compound and potential MOA.